Evidence map›Paper›PMID 36378400›Full record

ArticleJournal of neuro-oncology2023

Sporadic multiple intracranial meningioma does not infer worse patient outcomes: results from a case control study.

Abdurrahman I Islim, Jing X Lee, Mohammad A Mustafa, Christopher P Millward, Conor S Gillespie, George E Richardson, Basel A Taweel, Emmanuel Chavredakis, Samantha J Mills, Andrew R Brodbelt and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abdurrahman I IslimInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7BE, UK. a.islim@doctors.org.uk.
Jing X LeeManchester Centre for Clinical Neurosciences, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, UK.
Mohammad A MustafaInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7BE, UK.
Christopher P MillwardInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7BE, UK.
Conor S GillespieInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7BE, UK.
George E RichardsonInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7BE, UK.
Basel A TaweelInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7BE, UK.
Emmanuel ChavredakisInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7BE, UK.
Samantha J MillsDepartment of Neuroradiology, The Walton Centre NHS Foundation Trust, Liverpool, UK.
Andrew R BrodbeltInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7BE, UK.
Michael D JenkinsonInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7BE, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSporadic multiple meningioma are uncommon. Population-based data suggests that these patients have a reduced overall survival when compared to patients with solitary meningioma. The aim of this study was to investigate the clinical outcomes in multiple and solitary meningioma.

methodsA single-center matched cohort study (2008-2018) was performed. Patients with synchronous multiple meningioma at presentation, with no history of prior intracranial radiation, concurrent hormone replacement therapy or features of NF2-schwannomatosis were included. Eligible patients were matched 1:1 to patients with solitary meningioma. Outcomes of interest were occurrence of an intervention, recurrence, new meningioma development and mortality.

resultsThirty-four patients harboring 76 meningioma at presentation were included. Mean age was 59.3 years (SD = 13.5). Thirty-one (91.2%) were female. The median number of meningioma per patient was 2 (range 2-6). Eighteen patients (52.9%) were symptomatic at presentation. Median overall follow-up was 80.6 months (IQR 44.1-99.6). Compared to patients with a sporadic meningioma, there was no difference in intervention rates (67.6% vs 70.6%, P = 0.792). Eight patients (34.8%) with a multiple meningioma had a WHO grade 2 meningioma compared to 7 (29.2%) with a solitary meningioma (P = 0.679). Median recurrence-free survival was 89 months (95% CI 76-104) with no difference between the two groups (P = 0.209). Mean overall survival was 132 months (95% CI 127-138) with no difference between the two groups (P = 0.860). One patient with multiple meningioma developed two further new meningioma 36 months following diagnosis.

conclusionSporadic multiple meningioma may not have worse clinical outcomes. Management of patients with sporadic multiple meningioma should be tailored towards the symptomatic meningioma or high-risk asymptomatic meningioma.

Indexed as

Meningeal NeoplasmsMeningiomaCase-Control StudiesCohort StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective Studies

Identifiers

PMID36378400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.